Phosphodiesterase type-5 inhibitor and oxidative stress

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 4, 2008, Pages 879-889

  Speranza, Lorenza ^a   Franceschelli, S ^a   Pesce, M ^a   Vinciguerra, I ^a   De Lutiis, M A ^a   Grilli, A ^a,b   Felaco, M ^a   Patruno, A ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b University Leonardo Da Vinci Torrevecchia Teatina   (Italy)

Author keywords

Erectile dysfunction; Nitric oxide; Phosphodiesterase type 5 inhibitors

Indexed keywords

CATALASE; CITRULLINE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; WESTERN BLOTTING;

EID: 59849118953     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100412     Document Type: Article

References (37)

1. NIH Consensus Development Panel on Impotence. Impotence: NIH Consensus Conference 1993; JAMA 270:83-90.
2. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and possible policy consequences. BJU Int 1999; 84:50-56.
3. Spector IP, Carey MP. Incidence and prevalence of the sexual dysfunction: A critical review of the empirical literature. Arch Sex Behav 1990; 19:389-408.
4. Melman A, Gingell CJ. The epidemiology and pathophysiology of erectile disfunction. J Urology 1999; 161:5-11.
5. Giuliano F, Allard J. Apomorphine SL (Uprima®): preclinical and clinical experience learned from the first central nervous system-acting ED drug. Int J Impot Res 2002; 14(1):S53-6.
6. Dula E, Bukofzer S, Perdok R, George M, Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL whith placebo and whith 4 mg apornorphine SL in male erectile dysfunction. Eur Urol 2001; 39:558-64.
7. Bukofzer S, Livesey N. Safety and tolerability of apomorphine SL (Uprima®). Int Impot Res 2001; 13(3):S40-4.
8. Uckert S, Kuthe A, Stief CG, Jonas U. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 2001; 19:14-22.
9. Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002; 60(SB): 67-90.
10. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (Viagra®) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10:69-74.
11. Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single dose. Eur Urol 2001; 40:181-90.
12. Gadau M, Fernandez A, Cuevas P, Martins T, Angulo J. Tadalafil (IC351) enhances NO-mediated relaxation of human arterial and trabeculare penile smooth muscle. Int J Impot Res 2001; 13 (S4):14.
13. Juilfs DH, Soderling S, Burns F, Beavo JA. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterase (PDE5). Rev Physiol Biochem Pharmacol 1999; 135:67-104.
14. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326:90-94.
15. Bonomini M, Pandolfi A, Di Pietro N, et al. Adherence of uremic erytrocytes to vascular endothelium decreases endothelial nitric oxide synthase expression. Kidney Int 2005; 65:1899-906.
16. Grilli A, De Lutiis MA, Patruno A, et al. Effect of chronic hypoxia on inducile nitric oxide synthase expression in rat myocardial tissue. Exp Biol Med 2003; 228:935-42.
17. Reale M, De Lutiis MA, Patruno A, et al. Modulation of MCP-1 and iNOS by 50 -Hz sinusoidal electromagnetic field. Nitric Oxide 2006; 15:50-7.
18. Pritchard KA, Groszek L, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77:510-8.
19. Sun M, Zigman S. An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Anal Biochem1978; 90:81-9.
20. Aebi HE. Catalase. In: Bergamaier HU eds Methods in enzymatic analysis, Verlag Chemie, Weinheim 1974; 2:673-84.
21. Paglia DE, Valentine WN. Studies on the qualitative and quantitative characterization of erythrocytes glutathione peroxidase. J Lab Clin Med 1967; 70: 158-69.
22. Di Ilio C, Sacchetta P, Lo Bello M, Caccuri G, Federici G. Selenium independent glutathione peroxidase activity associated with cationic forms of glutathione transferase in human hearth. J Mol Cell Cardiol 1986; 18:983-91.
23. Amicarelli F, Ragnelli AM, Aimola P, Bonfigli A, Colafarina S, Di Ilio C, Miranda M. Age-dependent ultrastructural alterations and biochemical response of rat skeletal muscle after hypoxic or hyperoxic treatments. Biochim Biophys Acta 1999; 1453(1): 105-14.
24. Aversa A, Bruzziches R, Vitale C, Marazzi G, Francomano D, Barbaro G, Spera G, Rosario GM. Chronic Sildenafil in men with diabete san erectile dysfunction. Exper Opin Drug Metab Toxicol 2007; 3:41-64.
25. Nevratil P. Erectile dysfunction, its relation to diabetes its management 2007. Vinitr Lek 2008; 54: 485-7.
26. Stuckey BG, Walsh JP, Ching HL, Stcukey AW, Palmer NR, Thomposon PL, Watts GF. Erectile dysfunction predicts generalised cardiovascular diseases: evidence from a case- control study. Atherosclerosis 2007; 194:458-64.
27. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26:1553-79.
28. Anderson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75:191-236.
29. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989; 321:1648-59.
30. Saenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2002; 14(S):S6-10.
31. Adaikan PG, Ng SC. Physiological significance of nitrergic transmission in human penile erection. Asian. J Androl 2000; 2:51-6.
32. Toda N, Avajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 2005; 106: 233-66.
33. Blanco R, Saenz de Tejadd I, Goldstein I, et al. Cholinergic neurotransmission in human corpus cavernosum II Acetylcholine synthesis. Am J Physiol 1988; 254:H468-72.
34. Dail WG, Hamill RW. Parasympathetic nerves in penile erectile tissue of the rat contain choline acetyltransferase. Brain Res 1989; 487:165-70.
35. Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs 2008; 68:231-8.
36. Halliwell B, Gutteridge JM. Free radical in biology and medicine.Oxford, UK: Oxford University Press 1999.
37. Pinho RA, Andrades ME, Oliveira MR, et al. Imbalance in SOD/CAT activities in rat skeletal muscles submitted to treadmill training exercise. Cell Biol Int 2006; 30:848-53.